OncLive TV

Dr. Callander on Selecting a Frontline Treatment Strategy in Multiple Myeloma

January 22nd 2021

Natalie S. Callander, MD, discusses selecting a frontline treatment strategy for patients with multiple myeloma.

Dr. Ciombor on the FDA Approval of Trastuzumab Deruxtecan in HER2+ Metastatic Gastric Cancer

January 22nd 2021

Kristen K. Ciombor, MD, MSCI, discusses the FDA approval of fam-trastuzumab deruxtecan-nxki in HER2-positive metastatic gastric cancer.

Dr. Hubbard on Sequencing Challenges With EGFR Inhibitors in CRC

January 22nd 2021

Joleen M. Hubbard, MD, discusses sequencing challenges regarding EGFR inhibitors in colorectal cancer.

Dr. Bekaii-Saab Discusses Indicators of Progression in CRC

January 22nd 2021

Tanios S. Bekaii-Saab, MD, FACP, discusses indicators of progression in colorectal cancer.

Dr. Choueiri on the FDA Approval of Nivolumab/Cabozantinib in mRCC

January 22nd 2021

Toni K. Choueiri, MD, discusses the FDA approval of nivolumab and cabozantinib in metastatic renal cell carcinoma.

Dr. Ahn on the Growing Role of ctDNA as a Biomarker in CRC

January 21st 2021

Daniel H. Ahn, DO, discusses the growing role of circulating tumor DNA in colorectal cancer.

Dr. Halmos on the Emergence of KRAS-Targeted Therapies in Lung Cancer

January 21st 2021

Balazs Halmos, MD, MS, discusses the emergence of KRAS-targeted therapies in lung cancer.

Dr. Burris on the Potential for Novel Checkpoint Inhibitor Combinations in Oncology

January 21st 2021

Howard A. “Skip” Burris, III, MD, FASCO, FACP, discusses the potential of novel combination strategies with checkpoint inhibitors in oncology.

Dr. Lin on the Importance of Developing non-BCMA–Targeting Agents in Myeloma

January 20th 2021

Yi Lin, MD, PhD, discusses the importance of developing non-BCMA–targeting agents in multiple myeloma.

Dr. Kumar on the Emergence of MRD Negativity as an End Point in Multiple Myeloma

January 20th 2021

Shaji K. Kumar, MD, discusses the emergence of minimal residual disease negativity as a surrogate end point in relapsed/refractory multiple myeloma.

x